Gregory T Moore (Gregory Moore)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Jack Feehan, Alexandra Mack, Caroline Tuck, Jorge Tchongue, Darcy Q Holt, William Sievert, Gregory T Moore, Barbora De Courten, Alexander Hodge
Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease-A Single Blinded Crossover Trial. Nutrients 15 (23) (2023)
Anke L Nguyen, Megan Burns, Madhuni Herath, Kate J Lambell, Darcy Q Holt, Jessica A Fitzpatrick, Frances Milat, Peter R Ebeling, Peter R Gibson, Gregory T Moore
Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics (2023)
Francis A Farraye, Taha Qazi, Paulo Gustavo Kotze, Gregory T Moore, Rajiv Mundayat, Nervin Lawendy, Puza P Sharma, Donna T Judd
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Alimentary pharmacology & therapeutics 54 (4) (2021)
Gregory T Moore
Editorial: UK quality of care drive improving ulcerative colitis hospital outcomes. Alimentary pharmacology & therapeutics 50 (5) (2020)
Emma K Flanagan, Peter R Gibson, Emily K Wright, Gregory T Moore, Miles Patrick Sparrow, William Connell, Michael A Kamm, Jakob Begun, Britt Christensen, Peter De Cruz, Edward Shelton, Damian Dowling, Jane M Andrews, Steven J Brown, Olga D Niewiadomski, Mark G Ward, Ourania Rosella, Gennaro Rosella, Katerina V Kiburg, Alyson L Ross, Sally J Bell, null null
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary pharmacology & therapeutics 52 (10) (2020)